Bachem Secures Financing of Strategic Growth Initiatives
Bachem (OTC: BCHMY) closed a CHF 500 million revolving credit facility with a five-year maturity and a non-committed option to increase by CHF 150 million.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bachem (OTC: BCHMY) closed a CHF 500 million revolving credit facility with a five-year maturity and a non-committed option to increase by CHF 150 million. UBS Switzerland AG acted as lead arranger and agent with a consortium of domestic and international banks. The financing refinances existing bilateral credit lines and is intended to support Bachem's strategic growth initiatives while strengthening operational and financial flexibility.
Positive
- CHF 500 million syndicated revolving credit facility secured
- Facility 5-year maturity provides multi-year financing visibility
- Non-committed increase option of CHF 150 million for additional flexibility
- UBS Switzerland AG led the syndication with domestic and international banks
Negative
- None.
Details
News Market Reaction – BCHMY
On Apr 27, the day this news came out, BCHMY closed 2.44% below the previous close.
Data tracked by StockTitan Argus for the Apr 27 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
| Media Release |
Bubendorf, Switzerland--(Newsfile Corp. - April 27, 2026) - Bachem Holding AG (SIX: BANB) (“Bachem”) announced today the closing of a revolving credit facility of CHF 500 million with a maturity of five years and a non-committed option to increase the facility by CHF 150 million.
The revolving credit facility was syndicated with UBS Switzerland AG acting as lead arranger and agent, together with a consortium of domestic and international banks. The financing supports the continued implementation of Bachem’s strategic initiatives while simultaneously strengthening the company’s operational and financial flexibility.
Alain Schaffter, CFO of Bachem, says: “The syndicated credit facility will refinance our existing bilateral credit lines. It provides us with a robust and flexible financing base, enabling us to systematically advance our strategic growth initiatives.”
About Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with its headquarters in Switzerland and sites in Europe and the US. The company is listed on the SIX Swiss Exchange.
For further information, see www.bachem.com.
For more information:
| Media Patrick Barth | Investors Barbora Blaha |
This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Bachem Holding AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Bachem Holding AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294334
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.